Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Atrium Therapeutics, Inc.NASDAQ: RNA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation of $0 in Q1 FY2026

Q1 FY2026 stock-based compensation was $0.

Context

  • Stock-based compensation amounted to 41.2% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$7.68M— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7.68M USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Stock-Based Compensation figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.